Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

308.08 +7.89 (+2.63%)
Official Closing Price Updated: 7:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Week In Review: RemeGen Raises $410 Million In Shanghai IPO For mAbs/Dual Therapies
RemeGen, a Yantai biotech with a portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Although the offering was oversubscribed, the company’s stock... 
Via Talk Markets
Exxon Mobil, Google Lead Five Stocks Near Buy Points For Resilient Portfolio
Exxon and Google lead diverse stocks to help navigate market shifts. 
Via Investor's Business Daily
4 Stocks Reporting Earnings the Week of April 4
Q4 2021 earnings season officially wraps up next week, but there are still a few companies left to report their financial results. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Lilly Presents Updated Data On Retevmo In Advanced RET Fusion-Positive Lung Cancer
 
Via Benzinga
House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month
The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.  
Via Benzinga
Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility
Vir Biotechnology remains under pressure despite its looming addition to a new index. 
Via Investor's Business Daily
If You Invested $100 In Eli Lilly 10 Years Ago, Here's How Much You Would Have Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.2% on an annualized basis producing an average annual return of 21.76%. Currently, Eli Lilly has a market capitalization of... 
Via Benzinga
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Biotech Funds and ETFs Continue to Lag
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are... 
Via Talk Markets
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
 
Via Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)  
Via Benzinga
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen’s Bavarian Nordic in a $225 million deal. The vaccine is aimed at older... 
Via Talk Markets
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
The  
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Insiders Sell About $138M Of 5 Stocks
The Russian ruble declined against the US dollar on Monday after the Moscow Exchange resumed trading of government debt securities. Investors, meanwhile, focused on some notable... 
Via Benzinga
Looking Into Eli Lilly and Company's Recent Short Interest
Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 13.56% since its last report. The company recently reported that it has 5.36 million shares sold short, which... 
Via Benzinga
World Markets News For Friday
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
Check Out What Whales Are Doing With LLY
Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Watch For Continued Gains In Shares Of Eli Lilly And Company
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Eli Lilly and Company (NYSE: LLY) ... 
Via Benzinga
Markets Rise
Markets in Asia and Europe rose today in hopes for the Chinese to provide economic support to these markets after it paid its bond debt. 
Via Talk Markets
Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease
 Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults... 
Via Benzinga
News-Filled Day
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
Executives Sell More Than $25M Of 4 Stocks
Although US crude oil futures traded sharply on Tuesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
Big U.S. Stocks’ Q4’21 Fundamentals
U.S. stock markets have suffered a major trend reversal this year, rolling over into a full-blown correction. 
Via Talk Markets
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
These four medical stocks are outperforming the lousy market for health care investors. 
Via Investor's Business Daily
Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis. Buying $100 In LLY: 5 years ago, an investor could have purchased 1.19... 
Via Benzinga
Meta Platforms And 4 Other Stocks Sold By Insiders
Although US crude oil futures traded higher this morning, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.